NCT01570179View on ClinicalTrials.gov

Sugammadex-dosing in Bariatric Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Neuromuscular Blockade
Interventions
DRUG

ideal BW based sugammadex reversal of moderate block

2 mg/kg sugammadex (based og ideal body weight)

DRUG

real body weight based sugammadex reversal of moderate block

2 mg/kg sugammadex (based on real BW)

DRUG

real body weight based sugammadex reversal of deep block

4 mg/kg sugammadex (based on real BW)

DRUG

ideal body weight based sugammadex reversal of deep block

4 mg/kg sugammadex (based on ideal BW)

Trial Locations (2)

54500

CHU Nancy, Vandœuvre-lès-Nancy

67091

CHU Strasbourg Hôpital Civil, Strasbourg

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT01570179 - Sugammadex-dosing in Bariatric Patients | Biotech Hunter | Biotech Hunter